PA
DFTX

Parallel Advisors’s Definium Therapeutics DFTX Stock Holding History

Parallel Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.4K Hold
232
– – ﹤0.01% 3082
2025
Q4 		$3.12K Hold
232
– – ﹤0.01% 3001
2025
Q3 		$2.74K Sell
232
-20
-8% -$187 ﹤0.01% 2970
2025
Q2 		$1.63K Buy
252
+233
+1,226% +$1.53K ﹤0.01% 3087
2025
Q1 		$111 Hold
19
– – ﹤0.01% 3436
2024
Q4 		$132 Sell
19
-700
-97% -$4.82K ﹤0.01% 3419
2024
Q3 		$4.09K Hold
719
– – ﹤0.01% 2679
2024
Q2 		$5.18K Buy
719
+700
+3,684% +$6.12K ﹤0.01% 2535
2024
Q1 		$179 Sell
19
-458
-96% -$2.61K ﹤0.01% 3161
2023
Q4 		$1.75K Hold
477
– – ﹤0.01% 2839
2023
Q3 		$1.49K Sell
477
-66
-12% -$271 ﹤0.01% 2895
2023
Q2 		$1.94K Hold
543
– – ﹤0.01% 2758
2023
Q1 		$1.72K Buy
543
+400
+280% +$1.33K ﹤0.01% 2817
2022
Q4 		$315 Hold
143
– – ﹤0.01% 3118
2022
Q3 		$1K Sell
143
-1,668
-92% -$16K ﹤0.01% 2958
2022
Q2 		$17K Buy
+1,811
New +$22.9K ﹤0.01% 1736

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Parallel Advisors's DFTX Position: Q1 2026 in Review

Parallel Advisors held its Definium Therapeutics (DFTX) position steady in Q1 2026 at 232 shares worth $4.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3082.

Parallel Advisors first reported a position in DFTX in Q2 2022 and has held it in 16 quarters since. The position peaked at $17K in Q2 2022. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • Parallel Advisors held 232 shares of Definium Therapeutics worth $4.4K as of Q1 2026.
  • Parallel Advisors left its Definium Therapeutics share count unchanged in Q1 2026.
  • Definium Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #3082 holding.
  • Parallel Advisors first reported a position in Definium Therapeutics in Q2 2022 and has held it in 16 quarters since.
  • Parallel Advisors's Definium Therapeutics position peaked at $17K in Q2 2022.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.